Published on
July 7, 2026
- 14:00 GMT
SuviCa, CU Boulder, and CU Anschutz Announce Positive FDA Pre-IND Feedback for SVC112 Program in Advanced Solid Tumors
BOULDER, CO, UNITED STATES, July 7, 2026 /EINPresswire.com/ -- SuviCa, Inc., along with the University of Colorado Boulder and the University of Colorado Anschutz, today announced the successful completion of a Type B Pre-Investigational New Drug (pre- …
Distribution channels:
Banking, Finance & Investment Industry, Education
...
